Australian Chemicals Stock News

Peninsula Energy recently reported that ramp-up at its Lance Uranium Project is progressing, with Mine Unit 4 outperforming early operational expectations and overall 2026 production guidance maintained despite issues at Mine Unit 3. The company also completed a fully subscribed A$69.9 million equity raising and fully drew a Davidson Kempner debt facility, lifting cash to about US$36 million to support continued development as uranium prices strengthen on improving global nuclear demand and...

Why 29Metals is back on investor radars 29Metals (ASX:29M) has drawn fresh attention after lodging a sizeable follow on equity offering of about A$149.8m, paired with a rights issue and an associated ex dividend date on January 21, 2026. The offer covers more than 374 million ordinary shares at A$0.40, issued at a A$0.022 discount per share, raising questions for existing and prospective shareholders about dilution, capital structure, and potential valuation resets. See our latest analysis...

Aeris Resources has now released its December 2025 quarterly results, reporting copper equivalent production of 10.1 kt, gold output above plan at Cracow, full repayment and cancellation of its A$50,000,000 WHSP debt facility, and regulatory consent for the Constellation project. Encouraging exploration outcomes, combined with balance sheet deleveraging and progress toward developing Constellation, signal a company focused on strengthening operational and project foundations. We’ll now look...

Why the upcoming Q2 call matters for Ramelius Resources Interest in Ramelius Resources (ASX:RMS) is picking up as investors look ahead to the Q2 2026 earnings call on 29 January, which is expected to update the market on financial and operational performance. See our latest analysis for Ramelius Resources. At a share price of A$4.72, Ramelius has seen a 13.46% 30 day share price return and 42.17% 90 day share price return. Its 1 year total shareholder return of 96.45% and very large 3 year...

Drilling results at Maverick Springs put Sun Silver back in focus Sun Silver (ASX:SS1) is back on investor radars after fresh drill assays at its Maverick Springs project in Nevada returned grades above the existing resource, including high-grade silver and antimony intervals that strengthen confidence in the geological model. See our latest analysis for Sun Silver. The high grade Maverick Springs assays come after a sharp run in the stock, with a 90 day share price return of 136.65% and a 1...

Insiders were net buyers of Kalgoorlie Gold Mining Limited's ( ASX:KAL ) stock during the past year. That is, insiders...

Insiders who bought PlaySide Studios Limited ( ASX:PLY ) in the last 12 months may probably not pay attention to the...

GFL International Co., Limited recently exited its substantial shareholder position in PLS Group Limited by selling 32.19 million shares at A$5.00 each, while traders focused on upcoming operational disclosures amid shifting lithium sentiment. This combination of a reshaped share register and heightened attention on quarterly production, costs, and lithium price exposure is sharpening interest in how PLS Group is positioned within the global battery materials supply chain. Against this...

Key Insights The projected fair value for Deterra Royalties is AU$5.05 based on 2 Stage Free Cash Flow to Equity With...

With its stock down 10.0% over the past week, it is easy to disregard COSOL (ASX:COS). However, the company's...

ImExHS Limited ( ASX:IME ) insiders who purchased shares in the last 12 months were richly rewarded last week. The...

ANZ Group Holdings recently confirmed plans to redeem A$1.25 billion of subordinated notes in February 2026 and separately decided to consolidate its Singapore workforce into a single Marina One office as leases expire. Together with heightened focus on the Reserve Bank of Australia’s upcoming rate decision and ANZ’s February trading update, these moves highlight how the bank is actively fine-tuning capital, funding and workplace settings. With these developments in mind, we’ll explore how...

Key Insights Significant control over Recce Pharmaceuticals by retail investors implies that the general public has...

Key Insights Significant control over Clarity Pharmaceuticals by individual investors implies that the general public...

Key Insights The considerable ownership by private companies in SGH indicates that they collectively have a greater say...

Peako Limited ( ASX:PKO ) insiders who acquired shares over the previous 12 months, can probably afford to ignore the...

By selling NZ$77k worth of Aroa Biosurgery Limited ( ASX:ARX ) stock at an average sell price of NZ$0.48 over the last...

Key Insights Significant control over Brazilian Rare Earths by private companies implies that the general public has...

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Key Insights ioneer's significant individual investors ownership suggests that the key decisions are influenced by...

VEEM (ASX:VEE) has had a rough three months with its share price down 59%. However, stock prices are usually driven by...

Regis Healthcare Limited has appointed former Ramsay Health Care Australia CEO Carmel Monaghan as an independent Non-Executive Director, with her role effective from 1 February 2026, adding over 30 years of healthcare experience to its board. Her mix of large-scale healthcare operations expertise, governance experience across Australian and European boards, and focus on innovation and workforce development is expected to materially influence how Regis shapes its care model and organisational...

With a price-to-earnings (or "P/E") ratio of 7.2x Central Petroleum Limited ( ASX:CTP ) may be sending very bullish...

Recent commentary around Medibank Private (ASX:MPL) has centred on its consistent earnings growth and dividend payouts, prompting investors to look more closely at what stable EPS and income distributions might mean for the stock. See our latest analysis for Medibank Private. At a share price of A$4.62, Medibank Private has seen a 7 day share price return of 1.54% but a 90 day share price return decline of 5.33%. Its 1 year total shareholder return of 20.03% and 5 year total shareholder...